
CLAIMS

What is claimed is:

1. A compound or a pharmaceutically acceptable salt thereof, wherein the compound is presented by formula (I):



(I)

wherein

Me = CH_3;

A = NR_5;

X = –OH, –O–Y–Z, –S–Y–Z, or –NR_5–Y–Z;

R_1 and R_2 are independently H, D, hydroxyl, alkoxy, nitrile, halogen atoms, C_1–C_{20} straight, branched or cyclo alkyl groups optionally substituted with halogen atoms; or

R_1 and R_2 are independently phenyl or benzyl groups being optionally substituted with one or more substituents selected from C_1–C_{20} straight, branched or cyclo alkyl groups, halo alkyl groups, hydroxyl, alkoxy, nitrile, nitro, amino, amide, ester, sulfone, sulfoxide, sulfonamide, and halogen atoms; or

R_1 and R_2 are independently a heterocyclic saturated, unsaturated or aromatic 5- or 6-member ring containing one or more heteroatoms selected from nitrogen, oxygen and sulfur and being optionally substituted with one or more substituents selected from C_1–C_{20} straight, branched or cyclo alkyl, halo alkyl groups, hydroxyl, alkoxy, nitrile, nitro, amino, amide, ester, sulfone, sulfoxide or halogen atoms;

R_3 and R_4 are independently hydrogen, C_1–C_{10} straight or branched or cyclo alkyl or halo alkyl groups or


R_3 and R_4 can combine to form 3- to 6-membered rings;


R_5 = H, a C_1–C_{20} straight or branched alkyl groups, or a C_1–C_{10} straight or branched haloalkyl groups;


Y is a bivalent radical having the following meaning:


a) Straight or branched C_1 – C_{20} alkyl, being optionally substituted with one or more of the substituents selected from the group consisting of: halogen atoms and hydroxyl;

b) –C(O)(C_1–C_{10} alkyl)– or –C(O)$(CH_2)_n$C(O)O–(C_1–C_{10} alkyl)– or –(C_1–C_{10} alkyl) –;

c) ;

d) ;

e) ; or

f) 



wherein *n* is an integer from 0 to 20;



R^6 and R^7 are independently H or C_1–C_{10}, straight or branched alkyl groups, C_1–C_{10} straight or branched haloalkyl groups; or

R^6 and R^7 can combine to form 3- to 6-membered rings; and

Z is H, –OH, $C_{1\text{-}6}$ alkoxy, –COOH, $–NR^8R^9$;

R^8 and R^9 are independently C_1 – C_{20} alkyl, being optionally substituted with one or more substituents selected from hydroxyl, amino, ester, carboxylic acid, and halogen atoms; or

R^8 and R^9 can combine to form 3- to 6-membered rings containing one or more heteroatoms which are selected from the group consisting of: , , and .

2. The compound or the pharmaceutically acceptable salt thereof according to claim 1, wherein the compound is  or 

3. A pharmaceutical composition comprising: (1) a compound of claim 1 and/or a pharmaceutically acceptable salt thereof; and (2) one or more pharmaceutically acceptable carriers.

4. The composition according to claim 3, wherein said composition is a topical composition.
5. The composition according to claim 3, wherein said composition is an ophthalmically compatible composition.
6. The composition according to claim 5, wherein said composition is a topical composition.
7. The composition according to claim 5, wherein said composition comprises a therapeutically effective amount of said compound, and/or said pharmaceutically acceptable salt.
8. The composition according to claim 7, wherein said composition is a topical composition.
9. The composition according to claim 5, wherein said composition comprises from about 0.01 to about 10.0 weight percent of said compound and/or said pharmaceutically acceptable salt.
10. The composition according to claim 9, wherein said composition is a topical composition.
11. The composition according to claim 5, wherein said composition comprises: from about 0.01 percent weight/volume to about 5 weight/volume percent of said compound and/or said pharmaceutically acceptable salt; or from about 0.1 to 5.0 weight percent of said compound and/or said pharmaceutically acceptable salt.
12. The composition according to claim 11, wherein said composition is a topical composition.
13. A combination comprising: (1) a therapeutically effective amount of a compound according to claim 1 and/or a pharmaceutically acceptable salt thereof; and (2) one or more therapeutically active agents.
14. Use of a compound according to claim 1 and/or a pharmaceutically acceptable salt thereof in the manufacture of medicament for the treatment of a mammalian subject having or at risk of having an ocular disorder, wherein an effective amount of the medicament is to be administered to the subject.
15. The compound according to claim 1 and/or a pharmaceutically acceptable salt thereof for use the treatment of a mammalian subject having or at risk of having an ocular disorder.